8 completed, 1 unknown. 9 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 8, Unknown 1 |
| Phase 2 | 1 | Completed 1 |
Follow Type2diabetes: new trials by email Literature Review of Type2diabetes trials Research Report on Type2diabetes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant Exenatide Implant, Bydureon BCise (exenatide extended release), Semaglutide, 1.0 mg/mL - Overweight and Obesity, Type2diabetes | Phase 1 | Completed | Vivani Medical, Inc | 24 | 2024-12-20 | 2025-09-23 |
| Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants Arm 1 - DehydraTECH-CBD alone, Arm 2 - DehydraTECH-semaglutide alone, Arm 3 - DehydraTECH-CBD in combination with DehydraTECH-semaglutide - Type2diabetes | Phase 1 | Completed | Lexaria Bioscience Corp. | 148 | 2024-12-04 | 2026-01-12 |
| The Attractive 2 Trial - Pharmacokinetics of ATR-258 Oral Capsule vs. Oral Solution Formulations in Healthy Volunteers ATR-258 Oral solution, ATR-258 Oral capsule - Type2diabetes | Phase 1 | Completed | Atrogi AB | 21 | 2024-04-24 | 2024-07-01 |
| Bioequivalence Study to Compare Empagliflozin/ Metformin HCl 12.5mg/1000mg Film-coated Tablets Emapgliflozin/Metformin 12.5mg/1000mg Film-coated tablets, Synjardy® 12.5mg/1000mg film-coated tablets - Type2diabetes | Phase 1 | Completed | Humanis Saglık Anonim Sirketi | 36 | 2024-01-04 | 2024-06-10 |
| A Trial to Evaluate the Effect of C21 on Endothelial Dysfunction in Subjects With Type 2 Diabetes C21 - Type2diabetes, Endothelial Dysfunction | Phase 1 | Completed | Vicore Pharma AB | 11 | 2023-03-31 | 2024-11-12 |
| The Effects of Glucagon on Hepatic Metabolism Glucagon response study - Obesity, Type2diabetes | Phase 1 / Phase 2 | Completed | Adrian Vella | 21 | 2022-10-20 | 2026-11-04 |
| Study to Evaluate the Pharmacokinetic Characteristics of Pegylated Exenatide Injection (PB-119) in Subjects With Different Degrees of Renal Insufficiency and Matched Subjects With Normal Renal Function PB119 - Type2Diabetes | Phase 1 | Unknown | PegBio Co., Ltd. | 24 | 2022-05-01 | 2022-04-14 |
| A Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393(2) in Healthy Volunteers Under Fed Conditions CKD-393(2), CKD-501, D759, D150, D029 - Type2Diabetes | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 31 | 2022-04-21 | 2022-06-30 |
| A Study to Assess 11 Beta-hydroxysteroid Dehydrogenase Type 1 Inhibition in Adipose Tissue by SPI-62 SPI-62, Cortisone-d8 - Type 2 Diabetes Mellitus in Obese, Obesity | Phase 1 | Completed | Sparrow Pharmaceuticals | 12 | 2021-07-23 | 2024-04-22 |
Obesity (3) · Fatty Liver (1) · Insulin Resistance (1) · Non-alcoholic Fatty Liver Disease (1) · Overweight (1)
Body Weight (3) · Nutrition Disorders (3) · Nutritional and Metabolic Diseases (3) · Overnutrition (3) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Overweight (2) · Digestive System Diseases (1) · Glucose Metabolism Disorders (1) · Hyperinsulinism (1) · Liver Diseases (1) · Metabolic Diseases (1)
semaglutide (2) · Anti-Inflammatory Agents (1) · Exenatide (1) · Glucagon (1) · Glucocorticoids (1) · Metformin (1) · Single Person (1) · compound 21 (1) · lobeglitazone (1)
Adrian Vella (1) · Atrogi AB (1) · Chong Kun Dang Pharmaceutical (1) · Humanis Saglık Anonim Sirketi (1) · Lexaria Bioscience Corp. (1) · PegBio Co., Ltd. (1) · Sparrow Pharmaceuticals (1) · Vicore Pharma AB (1) · Vivani Medical, Inc (1)
Australia (2) · Sweden (2) · United States (2) · China (1) · Jordan (1) · South Korea (1)
Adrian Vella (1) · David Katz, PhD (1) · Erik Waara (1) · Jia Miao, MD,PhD (1) · Lisa Porter, MD (1) · Min Gul Kim, M.D, Ph.D. (1) · Ping Fu, MD,PhD (1)
2023 (2), R01DK116231 (1)